Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada

Reuters

2025/08/22

<a href="https://laohu8.com/S/MRNA">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada

CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2561477983"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561477983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561477983?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561477983","market":"nz","top_or_hot":-1,"title":"Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-22 21:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇圖資本持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDLbtYKdL:1","article_id":"2561477983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561477983","pubTimestamp":1755869156,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4501":"段永平概念","MRNA":"Moderna, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BK4139":"生物科技","BK4548":"巴美列捷福持仓","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"Moderna获得加拿大卫生部批准针对变种LP.8.1的更新COVID-19疫苗，并在加拿大生产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n    \n\n        CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}